← All trials
NCT06827327
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 28, 2025
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2026
- First posted
- Feb 14, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 650
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- RDC Clinical Pty LtdLead sponsor
- Kyowa KirinCollaborator
- Kyowa KirinOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.